SCHEMBL1332483

SCHEMBL1332483

CCCn1c(=O)c2c(nc(Cc3nnn[nH]3)n2CCN(CC)CCO)n(CCc2ccc([N+](=O)[O-])cc2)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.48
ADORA2B P29275 8/20 0.36
ADORA3 P0DMS8 4/20 0.36
ADORA2A P29274 2/20 0.35
OPRM1 P35372 1/20 0.35
KCNH2 Q12809 2/20 0.35
SLC22A2 O15244 1/20 0.34
ADRB1 P08588 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC47A2 Q86VL8 1/20 0.34
SLC47A1 Q96FL8 1/20 0.34
CYP3A4 P08684 2/20 0.34
PDE5A O76074 2/20 0.34
PDE4A P27815 2/20 0.34
PDE4B Q07343 2/20 0.34
PDE4C Q08493 2/20 0.34
PDE4D Q08499 2/20 0.34
TSHR P16473 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1334431 0.90 ADORA1 (0.61) ADORA1ADORA2BADORA3ADORA2ACYP3A4
SCHEMBL1333168 0.87 ADORA1 (0.52) ADORA1ADORA2BADORA3ADORA2AOPRM1
SCHEMBL1334396 0.85 ADORA1 (0.49) ADORA1ADORA2BADORA3ADORA2AOPRM1
SCHEMBL1334709 0.85 ADORA2B (0.35) ADORA1ADORA2BADORA3ADORA2ACYP3A4
SCHEMBL1334703 0.84 ADORA2B (0.37) ADORA1ADORA2BADORA3ADORA2ACYP3A4
SCHEMBL1333504 0.83 ADORA1 (0.49) ADORA1ADORA2BADORA3ADORA2AOPRM1
SCHEMBL1332546 0.83 ADORA1 (0.51) ADORA1ADORA2BADORA3ADORA2AOPRM1
SCHEMBL1333213 0.83 ADORA1 (0.49) ADORA1ADORA2BADORA3ADORA2AOPRM1
SCHEMBL1333442 0.83 ADORA1 (0.46) ADORA1ADORA2BADORA3ADORA2APDE4A
SCHEMBL1332479 0.82 ADORA1 (0.46) ADORA1ADORA2BADORA2AOPRM1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110282031-A1 A1 ADENOSINE RECEPTOR DIAGNOSTIC PROBES WILSON CONSTANCE N (US) 2011-11-17 US disclosed
US-7902360-B2 e.g. 3-[2-(4-aminophenyl)ethyl]-8-benzyl-7-(2-ethylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility WILSON CONSTANCE N 2011-03-08 US disclosed
EP-1636229-A4 A1 ADENOSINE RECEPTOR ANTOGONISTS ENDACEA INC (US) 2008-07-30 EP disclosed
US-20070282105-A1 A1 ADENOSINE RECEPTOR ANTAGONISTS ENDACEA, INC. (US) 2007-12-06 US disclosed
US-7247639-B2 A1 adenosine receptor antagonists ENDACEA, INC. (US) 2007-07-24 US disclosed
EP-1636229-A2 A1 ADENOSINE RECEPTOR ANTOGONISTS Endacea, Inc. (US) 2006-03-22 EP disclosed
US-20050187226-A1 A1 adenosine receptor antagonists ENDACEA, INC. 2005-08-25 US disclosed
WO-2005009343-A2 A1 ADENOSINE RECEPTOR ANTOGONISTS ENDACEA, INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110282031-A1 A1 ADENOSINE RECEPTOR DIAGNOSTIC PROBES ADORA1, ADORA3, ADORA2A ADORA1 1/4885ADORA2B 4/4885ADORA3 2/4885
US-20070282105-A1 A1 ADENOSINE RECEPTOR ANTAGONISTS ADORA1, ADORA3, ADORA2A ADORA1 1/4885ADORA2B 4/4885ADORA3 2/4885
US-20050187226-A1 A1 adenosine receptor antagonists ADORA1, ADORA2A, ADORA3 ADORA1 1/4885ADORA2B 4/4885ADORA3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.